Approval · Notice of Compliance 22949 · 2019
OFEV: Notice of Compliance 22949
Issued November 22, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22949
- Date
- November 22, 2019
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- To seek a new indication for the treatment of systemic scerosis asociated interstitial lung disease (SSc-ILD)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OFEV | Not yet assigned | — |
Medicinal ingredients
- NINTEDANIB 150 MG per CAP
- NINTEDANIB 100 MG per CAP